OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Rebecca Simpson, Erin R. Shanahan, Richard A. Scolyer, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 10, pp. 697-715
Closed Access | Times Cited: 53
Rebecca Simpson, Erin R. Shanahan, Richard A. Scolyer, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 10, pp. 697-715
Closed Access | Times Cited: 53
Showing 1-25 of 53 citing articles:
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Jian Sheng Loh, Wen Qi Mak, Li Tan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 219
Jian Sheng Loh, Wen Qi Mak, Li Tan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 219
Immunosurveillance in clinical cancer management
Guido Kroemer, Timothy A. Chan, Alexander M.M. Eggermont, et al.
CA A Cancer Journal for Clinicians (2023) Vol. 74, Iss. 2, pp. 187-202
Open Access | Times Cited: 59
Guido Kroemer, Timothy A. Chan, Alexander M.M. Eggermont, et al.
CA A Cancer Journal for Clinicians (2023) Vol. 74, Iss. 2, pp. 187-202
Open Access | Times Cited: 59
Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
Jiawen Cui, Yao Li, Yang Yang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116203-116203
Open Access | Times Cited: 36
Jiawen Cui, Yao Li, Yang Yang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116203-116203
Open Access | Times Cited: 36
Clinical and translational attributes of immune-related adverse events
Karijn P.M. Suijkerbuijk, Mick J M van Eijs, Femke van Wijk, et al.
Nature Cancer (2024) Vol. 5, Iss. 4, pp. 557-571
Closed Access | Times Cited: 33
Karijn P.M. Suijkerbuijk, Mick J M van Eijs, Femke van Wijk, et al.
Nature Cancer (2024) Vol. 5, Iss. 4, pp. 557-571
Closed Access | Times Cited: 33
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
Nicoletta Colombo, Elena Biagioli, Kenichi Harano, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 9, pp. 1135-1146
Closed Access | Times Cited: 30
Nicoletta Colombo, Elena Biagioli, Kenichi Harano, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 9, pp. 1135-1146
Closed Access | Times Cited: 30
The oral–gut microbiome axis in health and disease
Benoît J. Kunath, Charlotte De Rudder, Cédric C. Laczny, et al.
Nature Reviews Microbiology (2024) Vol. 22, Iss. 12, pp. 791-805
Closed Access | Times Cited: 23
Benoît J. Kunath, Charlotte De Rudder, Cédric C. Laczny, et al.
Nature Reviews Microbiology (2024) Vol. 22, Iss. 12, pp. 791-805
Closed Access | Times Cited: 23
Microbiome bacterial influencers of host immunity and response to immunotherapy
Yeganeh Yousefi, Kelly J. Baines, Saman Maleki Vareki
Cell Reports Medicine (2024) Vol. 5, Iss. 4, pp. 101487-101487
Open Access | Times Cited: 14
Yeganeh Yousefi, Kelly J. Baines, Saman Maleki Vareki
Cell Reports Medicine (2024) Vol. 5, Iss. 4, pp. 101487-101487
Open Access | Times Cited: 14
Role of the gut microbiota in tumorigenesis and treatment
Qingya Liu, Yun Yang, Meng Pan, et al.
Theranostics (2024) Vol. 14, Iss. 6, pp. 2304-2328
Open Access | Times Cited: 11
Qingya Liu, Yun Yang, Meng Pan, et al.
Theranostics (2024) Vol. 14, Iss. 6, pp. 2304-2328
Open Access | Times Cited: 11
Long-term relapse-free survival enabled by integrating targeted antibacteria in antitumor treatment
Yuanlin Wang, Yaqian Han, Chenhui Yang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 10
Yuanlin Wang, Yaqian Han, Chenhui Yang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 10
The role of microbial indole metabolites in tumor
Dingjiacheng Jia, Zheng Kuang, Liangjing Wang
Gut Microbes (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 9
Dingjiacheng Jia, Zheng Kuang, Liangjing Wang
Gut Microbes (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 9
Gut Microbiota Secondary Metabolites: Key Roles in GI Tract Cancers and Infectious Diseases
Eman K. E. Anwer, Muhammad Ajagbe, Mohamed Sherif, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 100-100
Open Access | Times Cited: 1
Eman K. E. Anwer, Muhammad Ajagbe, Mohamed Sherif, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 100-100
Open Access | Times Cited: 1
Intra-tumoral bacteria in breast cancer and intervention strategies
Ting Hou, Xiaoling Huang, Jiahui Lai, et al.
Advanced Drug Delivery Reviews (2025), pp. 115516-115516
Closed Access | Times Cited: 1
Ting Hou, Xiaoling Huang, Jiahui Lai, et al.
Advanced Drug Delivery Reviews (2025), pp. 115516-115516
Closed Access | Times Cited: 1
Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies
D.Y. Luo, Jing Zhou, Shuiliang Ruan, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
D.Y. Luo, Jing Zhou, Shuiliang Ruan, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
The combination of flaxseed lignans and PD-1/ PD-L1 inhibitor inhibits breast cancer growth via modulating gut microbiome and host immunity
Hao Wu, J.F. Liu, Xinghua Zhang, et al.
Drug Resistance Updates (2025) Vol. 80, pp. 101222-101222
Open Access | Times Cited: 1
Hao Wu, J.F. Liu, Xinghua Zhang, et al.
Drug Resistance Updates (2025) Vol. 80, pp. 101222-101222
Open Access | Times Cited: 1
Immune checkpoint inhibitors and acute kidney injury
Ping Zhou, Ying Gao, Zhijuan Kong, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Ping Zhou, Ying Gao, Zhijuan Kong, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Gut microbial metabolites in cancer therapy
Panwei Song, Zhi Peng, Xiaohuan Guo
Trends in Endocrinology and Metabolism (2024)
Closed Access | Times Cited: 5
Panwei Song, Zhi Peng, Xiaohuan Guo
Trends in Endocrinology and Metabolism (2024)
Closed Access | Times Cited: 5
Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes
Jiexi Yan, Lu Yang, Qingmiao Ren, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Jiexi Yan, Lu Yang, Qingmiao Ren, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Combining gut microbiota modulation and immunotherapy: A promising approach for treating microsatellite stable colorectal cancer
Yujie Chang, Min Long, Hanguo Shan, et al.
Critical Reviews in Oncology/Hematology (2025) Vol. 208, pp. 104629-104629
Closed Access
Yujie Chang, Min Long, Hanguo Shan, et al.
Critical Reviews in Oncology/Hematology (2025) Vol. 208, pp. 104629-104629
Closed Access
Therapeutic role of gut microbiota in lung injury-related cognitive impairment
Yanxia Cheng, Guangtao Hu, Lin Deng, et al.
Frontiers in Nutrition (2025) Vol. 11
Open Access
Yanxia Cheng, Guangtao Hu, Lin Deng, et al.
Frontiers in Nutrition (2025) Vol. 11
Open Access
Identification of intratumoral microbiome-driven immune modulation and therapeutic implications in diffuse large B-cell lymphoma
Zheng Yijia, Xiaoyu Li, Li‐Na Ma, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 4
Open Access
Zheng Yijia, Xiaoyu Li, Li‐Na Ma, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 4
Open Access
Exosomes in Precision Oncology and Beyond: From Bench to Bedside in Diagnostics and Therapeutics
Emile M. Youssef, Dannelle Palmer, Brandon Fletcher, et al.
Cancers (2025) Vol. 17, Iss. 6, pp. 940-940
Open Access
Emile M. Youssef, Dannelle Palmer, Brandon Fletcher, et al.
Cancers (2025) Vol. 17, Iss. 6, pp. 940-940
Open Access
Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
Stephen L. Wang, Timothy A. Chan
Cancer Cell (2025)
Closed Access
Stephen L. Wang, Timothy A. Chan
Cancer Cell (2025)
Closed Access
Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer
Maximilian Marhold, Simon Udovica, A. Halstead, et al.
OncoImmunology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 11
Maximilian Marhold, Simon Udovica, A. Halstead, et al.
OncoImmunology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 11
Influence of gut microbiota on systemic immune responses and cancer immunotherapy
Swathi P. Murakonda, Sriram Balusu, Haritha Chava, et al.
International review of cell and molecular biology (2025)
Closed Access
Swathi P. Murakonda, Sriram Balusu, Haritha Chava, et al.
International review of cell and molecular biology (2025)
Closed Access
Overview on biomarkers for immune oncology drugs
Evgeny N. Imyanitov, Elena V. Preobrazhenskaya, Natalia V. Mitiushkina
Exploration of Targeted Anti-tumor Therapy (2025) Vol. 6
Open Access
Evgeny N. Imyanitov, Elena V. Preobrazhenskaya, Natalia V. Mitiushkina
Exploration of Targeted Anti-tumor Therapy (2025) Vol. 6
Open Access
